PMID- 20199482
OWN - NLM
STAT- MEDLINE
DCOM- 20100603
LR  - 20220316
IS  - 1751-7893 (Electronic)
IS  - 1751-7885 (Linking)
VI  - 4
IP  - 1
DP  - 2010 Feb
TI  - Paliperidone extended-release tablets in patients with recently diagnosed 
      schizophrenia.
PG  - 64-78
LID - 10.1111/j.1751-7893.2010.00165.x [doi]
AB  - AIM: Effective early and persistent antipsychotic treatment in recently diagnosed 
      schizophrenia may positively impact long-term outcomes. Paliperidone 
      extended-release (ER) was assessed in this population. METHODS: Post hoc analysis 
      of pooled data from three 6-week, double-blind (DB), placebo-controlled, and 
      three 1-year open-label (OL) studies of paliperidone ER in schizophrenia 
      patients. Data stratified by time since diagnosis (< or =3 vs. >3 years). 
      RESULTS: At DB (n = 1193) and OL baselines (n = 744), 259 (21.9%) and 188 (25.3%) 
      patients were diagnosed < or =3 years. At DB end point, both populations improved 
      with paliperidone ER versus placebo on Positive and Negative Syndrome Scale 
      (PANSS) total, Clinical Global Impressions-Severity and Personal and Social 
      Performance (PSP) scale scores (all P < 0.05). At OL end point, there were 
      significant improvements from DB baseline in both populations on these scales (P 
      < 0.0001), with greater improvement in the < or =3-year population on PANSS total 
      (P < 0.001) and PSP (P < 0.001) scores. During DB treatment, only the < or 
      =3-year population reported adverse events (AEs) in > or =5% (placebo-adjusted 
      rate) of subjects receiving paliperidone ER: akathisia, extrapyramidal disorder 
      not otherwise specified and somnolence. During OL treatment, akathisia and 
      somnolence occurred more frequently (> or =5%) in the < or =3- versus >3-year 
      population. OL study completion rates were 51.1% in < or =3-year, and 48.2% in 
      >3-year subjects. CONCLUSIONS: Paliperidone ER significantly improved symptoms 
      and functioning in schizophrenia patients, regardless of time since diagnosis. 
      Recently diagnosed patients who continued treatment exhibited greater symptom 
      reduction and functional benefit over the long term. Results also suggest that 
      these patients may be more susceptible to certain AEs.
FAU - Canuso, Carla M
AU  - Canuso CM
AD  - Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA. 
      ccanuso@its.jnj.com
FAU - Bossie, Cynthia A
AU  - Bossie CA
FAU - Amatniek, Joan
AU  - Amatniek J
FAU - Turkoz, Ibrahim
AU  - Turkoz I
FAU - Pandina, Gahan
AU  - Pandina G
FAU - Cornblatt, Barbara
AU  - Cornblatt B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Early Interv Psychiatry
JT  - Early intervention in psychiatry
JID - 101320027
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
RN  - 0 (Isoxazoles)
RN  - 0 (Pyrimidines)
RN  - R8P8USM8FR (Paliperidone Palmitate)
SB  - IM
MH  - Adult
MH  - Akathisia, Drug-Induced/complications
MH  - Antipsychotic Agents/*administration & dosage/adverse effects
MH  - Delayed-Action Preparations/administration & dosage/adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Isoxazoles/*administration & dosage/adverse effects
MH  - Male
MH  - Paliperidone Palmitate
MH  - Psychiatric Status Rating Scales
MH  - Pyrimidines/*administration & dosage/adverse effects
MH  - Randomized Controlled Trials as Topic
MH  - Schizophrenia/complications/diagnosis/*drug therapy
MH  - Schizophrenic Psychology
MH  - Severity of Illness Index
MH  - Time Factors
EDAT- 2010/03/05 06:00
MHDA- 2010/06/04 06:00
CRDT- 2010/03/05 06:00
PHST- 2010/03/05 06:00 [entrez]
PHST- 2010/03/05 06:00 [pubmed]
PHST- 2010/06/04 06:00 [medline]
AID - EIP165 [pii]
AID - 10.1111/j.1751-7893.2010.00165.x [doi]
PST - ppublish
SO  - Early Interv Psychiatry. 2010 Feb;4(1):64-78. doi: 
      10.1111/j.1751-7893.2010.00165.x.